Maximus
Maximus Tribe, enclomiphene-led DTC hormone platform
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Prescribes enclomiphene off-label; enclomiphene is not FDA-approved for hypogonadism
Reference only. Not medical advice.
What can go wrong
Off-label use of an unapproved molecule shifts safety responsibility onto the compounding pharmacy and prescriber. SERMs can cause visual disturbances, mood changes, and other effects; long-term safety data specific to enclomiphene for chronic hypogonadism management is limited. Company white-paper data is not a substitute for regulated trials.
This is something to take to a clinician. The Atlas can tell you what is known about maximus in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Maximus (Maximus Tribe) is a DTC platform whose flagship is an enclomiphene-based oral protocol marketed as a testosterone-raising, fertility-preserving alternative to injectable TRT. Enclomiphene is the trans-isomer of clomiphene; it was developed and tested for male hypogonadism by Repros Therapeutics, whose FDA application was not approved, so enclomiphene has no FDA approval for low testosterone and is prescribed off-label via compounding. Maximus promotes results from an internal white paper (reportedly ~79 participants) citing large average increases in total and free testosterone. Because this is company-generated, non-peer-reviewed data on an FDA-rejected indication, the efficacy claims should be treated with caution.
Built on a molecule the FDA declined to approve, sold with in-house data as the headline.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Enclomiphene is a selective estrogen receptor modulator that blocks estrogen feedback at the hypothalamus, increasing GnRH and therefore LH and FSH, which stimulate the testes to make more of the man's own testosterone. Unlike exogenous TRT, this pathway keeps the testicular axis active, which is the basis for the fertility-preservation marketing claim.
In-house data on a rejected molecule
Two things are true at once: the SERM mechanism is real and clomiphene/enclomiphene do raise testosterone in many hypogonadal men (supported by independent literature), AND enclomiphene specifically failed to secure FDA approval for this indication when Repros Therapeutics sought it. Maximus' headline efficacy figures come from its own white paper, not peer-reviewed independent trials. Company-generated numbers on an unapproved use are the weakest form of evidence a marketer can lead with.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
What it does to fertility
Unlike exogenous TRT, enclomiphene stimulates the endogenous axis and can preserve or even improve sperm parameters, which is the mechanistic basis for its fertility-preservation positioning; independent meta-analyses support testosterone increases with clomiphene/enclomiphene in hypogonadal men.
What people get wrong
Often saidMaximus' white paper proves the protocol works better than TRT
ActuallyAn internal, non-peer-reviewed company white paper on an FDA-rejected indication is marketing evidence, not regulatory-grade proof. The underlying SERM mechanism has independent support, but the specific headline figures are self-reported.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Flagship
- Enclomiphene oral protocol ('King' / testosterone protocols)
- Molecule
- Enclomiphene, trans-isomer of clomiphene
- FDA status
- Not approved for hypogonadism; Repros' application was rejected
- Key evidence
- Internal white paper, reportedly ~79 participants, company-run
- Route
- Oral, off-label via compounding
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Maximus. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Systematic review/meta-analysis of clomiphene/enclomiphene for male hypogonadism (independent)2020s
Supports testosterone increases with SERM therapy; distinct from any single company's marketing data
Maximus internal white paper (company-generated)company-run, ~79 participants
Reports large average total- and free-testosterone increases; not peer-reviewed, on an FDA-unapproved indication